Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 20;23(10):5729.
doi: 10.3390/ijms23105729.

Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis

Affiliations
Review

Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis

Konrad Kaminiów et al. Int J Mol Sci. .

Abstract

Neuronal ceroid lipofuscinoses (NCLs) are a group of rare, inherited, neurodegenerative lysosomal storage disorders that affect children and adults. They are traditionally grouped together, based on shared clinical symptoms and pathological ground. To date, 13 autosomal recessive gene variants, as well as one autosomal dominant gene variant, of NCL have been described. These genes encode a variety of proteins, whose functions have not been fully defined; most are lysosomal enzymes, transmembrane proteins of the lysosome, or other organelles. Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia. Depending on the mutation, these symptoms can vary, with respect to the severity and onset of symptoms by age. Currently, all forms of NCL are fatal, and no curative treatments are available. Herein, we provide an overview to summarize the current knowledge regarding the pathophysiology, genetics, and clinical manifestation of these conditions, as well as the approach to diagnosis.

Keywords: NCL; genetics; lysosomal storage disorders; neurodegenerative disorders; neuronal ceroid lipofuscinosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Chabrol B., Caillaud C., Minassian B. Neuronal ceroid lipofuscinoses. Handb. Clin. Neurol. 2013;113:1701–1706. doi: 10.1016/B978-0-444-59565-2.00038-1. - DOI - PubMed
    1. Nita D.A., Mole S.E., Minassian B.A. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016;18:73–88. doi: 10.1684/epd.2016.0844. - DOI - PubMed
    1. Mole S.E., Anderson G., Band H.A., Berkovic S.F., Cooper J.D., Kleine Holthaus S.M., McKay T.R., Medina D.L., Rahim A.A., Schulz A., et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019;18:107–116. doi: 10.1016/S1474-4422(18)30368-5. - DOI - PubMed
    1. Specchio N., Ferretti A., Trivisano M., Pietrafusa N., Pepi C., Calabrese C., Livadiotti S., Simonetti A., Rossi P., Curatolo P., et al. Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy. Drugs. 2021;81:101–123. doi: 10.1007/s40265-020-01440-7. - DOI - PubMed
    1. Nelvagal H.R., Lange J., Takahashi K., Tarczyluk-Wells M.A., Cooper J.D. Pathomechanisms in the neuronal ceroid lipofuscinoses. Biochim. Biophys. Acta-Mol. Basis Dis. 2020;1866:165570. doi: 10.1016/j.bbadis.2019.165570. - DOI - PubMed

Substances

LinkOut - more resources